intravesical oxybutynin

Intravesical oxybutynin is a liquid formulation of the anticholinergic drug oxybutynin chloride, administered directly into the bladder via catheterization. It is being evaluated by the Central Hospital, Nancy (CHRU-Nancy) in the Phase 3 POXIPEN trial for the treatment of neurogenic bladder dysfunction in children with spina bifida. The drug acts as a competitive antagonist of muscarinic acetylcholine receptors (primarily M1, M2, and M3 subtypes) in the bladder detrusor muscle. By blocking these receptors, it suppresses involuntary bladder contractions, increases maximal bladder capacity, and reduces intravesical pressure. The intravesical route is intended to provide high local concentrations of the drug while minimizing the systemic side effects, such as dry mouth and constipation, commonly associated with oral oxybutynin therapy.

Brand names

VESOXX

Other names

oxybutynin chlorideoxybutynin hydrochloride